Day 2, April 8

Funding and Partnering and Accelerating Development

Supply & Logistics
09:00

Chair’s opening remarks

Immune Profiling
09:00

Chair’s opening remarks

Cancer & Immunotherapy
09:00

Chair’s opening remarks

Respiratory
09:00

Chair's opening remarks

Emerging and Infectious
09:00

Chair's opening remarks

Clinical Development
09:00

Chair’s opening remarks

Bioprocess & Manufacture
09:00

Chair's opening remarks

Risk Assessment and Communication of Safety

Clinical trial logistics and product planning

Keynotes

Checkpoints & Combinations

RSV Vaccines Pipeline Update

Global Health Preparedness Strategy

Incorporating innovation to vaccine trials

Vaccine Bioprocessing Trends and Challenges

The Animal Health Business

Vaccine Safety
09:10

Panel: Mandatory vaccination policies around the world, are they working?

  • What has been the impact of the introduction of mandatory vaccination and other policies globally?
    • Has it had a positive impact overall or has it worsened polarization?
  • What have been the most successful strategies for communication?
  • Medical and religious exemptions
  • What is the relationship between the forcefulness of a policy and its impact on the rate of vaccination?
  • Using big data to analyze the spread of misinformation?
Cancer & Immunotherapy
09:10

Update on approaches to the development of clinical combination therapies

  • What are the fundamental principles of combination science?
  • Huge amounts of data have been generated from combination studies, how do you analyze these?
Clinical Development
09:10

Clinical trials of the future

  • Use of real-world evidence for vaccine efficacy
  • How to get information from the field to a database
  • Regulatory perspective in new development areas
Veterinary
09:10

Panel: The Future of the Animal Health Business

  • Discussing the emerging trends in animal health & biologics (companion and production animals)
  • The emergence of human health technologies in the animal health space; Are these technologies too expensive to implement in animal health?
  • The importance of establishing strong collaboration/partnerships for advancing animal health innovation
  • What about emerging markets? - Finding success in Latin America, China & India etc.
Cancer & Immunotherapy
09:40

Panel: Targeted approaches to combinations, what’s working?

  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?

Analysing Response Across Different Groups

Disruptive Technologies in the Animal Health Space

Supply & Logistics
10:10

Streamlining clinical trial operations through automation

Emerging and Infectious
10:10

Janssen’s Zika vaccine developments and new data

10:40

Networking Coffee Break

Vaccine Distribution

Target Discovery

Improving Clinical Performance in Respiratory Pathogens

Vaccine Development Processes & Global Health

Developing a Vaccine Revolution Against Infectious Diseases

Immune Profiling
11:40

Omics studies in vaccine trials to deduce markers & mechanisms of protection for effective immunity

  • Analysis of differences in response between resource rich and resource poor areas; what can we learn from this?
Cancer & Immunotherapy
11:40

Advances in the determination and prioritization of neoantigens for the development of neoantigen-specific cancer vaccines

Emerging and Infectious
11:40

Vaccine developments on a Chikungunya vaccine

Kelly Warfield, Vice President, Vaccine Research And Development, Emergent BioSolutions

Improving Clinical Efficacy

Supply & Logistics
12:10

Can we achieve global harmonization of regulatory requirements for vaccines

  • Managing regulatory requirements and timelines while rolling out vaccine globally
  • Variability of assays and tests required internationally
  • Practicalities are very challenging – how do big pharma manage this?
  • Insurance of process control – what will satisfy regulatory bodies downstream?
  • When and how should you engage with regulatory bodies
Partnerships
12:10

Showcase 3 - Developing HSV-1 vaccine that provides protection from HSV-2

Partnerships
12:25

Safety study of the first in human phase I trial with a novel RSV recombinant G protein-based vaccine

Informing Next Generation Vaccines

New Platform Derived Vaccines

Emerging and Infectious
12:40

Updates on CEPI’s priority pathogens: MERS, Lassa & Nipah virus vaccine development updates

Clinical Development
12:40

Overcoming challenges in seasonal vaccine studies

Partnerships
12:55

Showcase 6 - A live typhoid vaccine providing cross protection for parathyroid fever

13:10

Networking Lunch & Poster Session

Vaccine Safety Case Studies & Surveillance

A Deep Dive into Successful Partnering

Vaccine Safety
14:40

Panel: Unravelling dengue vaccine safety concerns: To what extend could they have been predicted?

  • Use of controlled human infection models
  • Need for complete assessment of viremia induced by the vaccine
  • The importance of balanced infectivity in live attenuated vaccines and balanced efficacy across age groups and sero-status
  • Surveillance:
    • Need for improved surveillance systems where dengue vaccine is introduced
    • How long should active surveillance continue?
    • Collection of blood samples – baseline & routinely scheduled collections
Supply & Logistics
14:40

Challenges and considerations for managing commercial vaccine supply chains

Cancer & Immunotherapy
14:40

Clinical development of mRNA vaccines for cancer

Bioprocess & Manufacture
14:40

Increasing production of live viral vaccines and vectors with novel bioreactor technologies

  • A historical perspective on adherent and non-adherent live-virus vaccine production and how recent advances in bioreactors allow for greater productivity and reduced costs per dose
Partnerships
14:40

Success case study 1 - How a network of research centers work together in a multidisciplinary effort to develop better influenza vaccines

Emerging and Infectious
14:55

ExpreS2 – An insect cell-based vaccine production system suitable for difficult-to-express proteins

Broadly Protective and Pandemic Influenza Vaccines

Vaccine Pipeline Updates of Highly Infectious Diseases

Supply & Logistics
15:10

Reducing timelines and costs of vaccine shipments

Immune Profiling
15:10

Panel: How can we use data to inform next generation vaccines?

  • Exploring immune profiling platforms to accelerate and de-risk vaccine development
  • Can modelling immune responses outside the body human help to do this?
  • How can we use big data to inform next generation vaccines?
Cancer & Immunotherapy
15:10

Hollow microneedle technology cancer vaccine delivery platforms

Reserved for 3M Drug Delivery Systems
Emerging and Infectious
15:10

Trials for emerging diseases and outbreaks: coronavirus

Technology & Cold Chain

Big Data

Vaccine Delivery & Manufacturing

Emerging and Infectious
15:40

Executing animal rule studies in high containment

Clinical Development
15:40

Impact of pre-existing immunity on the outcome of vector-based vaccine and gene therapy clinical trials: Evolution of delivery-vector viral neutralization assays

Partnerships
15:40

Success case study 3 - Immunizing the world – evaluating new vaccine programs and improving current immunization systems

16:10

Networking Coffee Break

Exploring trials in different populations

Improving Vaccine Uptake with Innovative Delivery Platforms

Vaccine Safety
16:40

Post-marketing assessment of vaccine safety in pregnancy

  • Key issues surrounding post-marketing safety surveillance for vaccines used during pregnancy
  • Update on changes in recently published Post-approval Pregnancy Safety Studies
Supply & Logistics
16:40

Cold chain technology solutions for going off-grid

Veterinary
16:40

Overcoming manufacturing challenges in the veterinary vaccine industry

  • Designing and commissioning high throughput manufacturing facilities
  • Facility and equipment design suitable for campaign production
  • Use of appropriate disposable technologies
  • Improving antigen yield through process optimization
Partnerships
16:40

Success case study 4 - Duke DARPA Pandemic Prevent Platform

Vaccine Safety
17:10

Vaccine safety surveillance: what can we do to improve surveillance studies and databases?

  • Evaluating vaccine safety in children and other at-risk populations
    • E.g. RSV and Pertussis, Live attenuated vs subunit
  • What are the benefits of RCTs and large databases and how can they be improved?
  • How can we ensure we are taking all parameters into account e.g. what time of year is the vaccine given?
  • How do we decide which signals are meaningful?
  • Do we need to revisit the influenza & narcolepsy issue?
  • The need for better databases in LMICs – how do you recognize safety signals? How can they be implemented?
Supply & Logistics
17:10

Ensuring the effective supply of temperature-sensitive vaccines for military personnel

Bioprocess & Manufacture
17:10

Alternative delivery system technology showcase

Erin Spiegel, Director Of Scientific Affairs, PharmaJet
Clinical Development
17:40

HPV vaccines in immunocompromised women and men

Bioprocess & Manufacture
17:55

How does different routes of delivery influence the immunological outcome?

  • Effectiveness and usability
18:10

Chair’s Closing Remarks and Close of Congress Day 2

18:15

Off-site Networking Drinks, follow the congress team Sponsored by Enesi Pharma

last published: 21/Feb/20 16:35 GMT